KR20060126659A - 키메라 항 cd44 항체 및 그 급성 골수성 백혈병 치료용용도 - Google Patents

키메라 항 cd44 항체 및 그 급성 골수성 백혈병 치료용용도 Download PDF

Info

Publication number
KR20060126659A
KR20060126659A KR1020067011975A KR20067011975A KR20060126659A KR 20060126659 A KR20060126659 A KR 20060126659A KR 1020067011975 A KR1020067011975 A KR 1020067011975A KR 20067011975 A KR20067011975 A KR 20067011975A KR 20060126659 A KR20060126659 A KR 20060126659A
Authority
KR
South Korea
Prior art keywords
antibody
ser
cells
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067011975A
Other languages
English (en)
Korean (ko)
Inventor
플로렌스 스마드자
존 이. 딕
장 카두셰
Original Assignee
인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르(인썸)
유니버시티 헬스 네트워크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르(인썸), 유니버시티 헬스 네트워크 filed Critical 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르(인썸)
Publication of KR20060126659A publication Critical patent/KR20060126659A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020067011975A 2003-11-19 2004-11-19 키메라 항 cd44 항체 및 그 급성 골수성 백혈병 치료용용도 Ceased KR20060126659A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292873.1 2003-11-19
EP03292873A EP1532984A1 (en) 2003-11-19 2003-11-19 Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia

Publications (1)

Publication Number Publication Date
KR20060126659A true KR20060126659A (ko) 2006-12-08

Family

ID=34429570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067011975A Ceased KR20060126659A (ko) 2003-11-19 2004-11-19 키메라 항 cd44 항체 및 그 급성 골수성 백혈병 치료용용도

Country Status (10)

Country Link
US (4) US20050147606A1 (cg-RX-API-DMAC7.html)
EP (3) EP1532984A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007513610A (cg-RX-API-DMAC7.html)
KR (1) KR20060126659A (cg-RX-API-DMAC7.html)
CN (1) CN1898268A (cg-RX-API-DMAC7.html)
AT (1) ATE480565T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004290918B2 (cg-RX-API-DMAC7.html)
CA (2) CA2484459A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004029078D1 (cg-RX-API-DMAC7.html)
WO (1) WO2005049082A2 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP2783700A1 (en) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
US20080118432A1 (en) * 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
CN101368173B (zh) * 2008-04-09 2011-12-28 协和干细胞基因工程有限公司 抗人cd44的工程抗体、载体、试剂盒及其用途
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
SI2531527T1 (sl) * 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
AU2011317211B2 (en) * 2010-10-22 2015-04-16 Dana-Farber Cancer Institute, Inc. Discovery of regulatory T cells programmed to suppress an immune response
BR112014010009A2 (pt) * 2011-10-26 2017-04-25 Univ California "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"
US20150151004A1 (en) * 2013-06-14 2015-06-04 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
CA3078963A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
WO2021160269A1 (en) * 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
US12673992B2 (en) 2020-02-13 2026-07-07 UCB Biopharma SRL Bispecific antibodies against CD9 and CD7
CN113552363B (zh) * 2020-04-03 2024-03-08 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
JP7869149B2 (ja) 2020-05-19 2026-06-02 アンスティテュ・クリー サイトカイン放出症候群の診断及び処置の方法
JP2024518200A (ja) 2021-05-18 2024-04-30 ヤンセン バイオテツク,インコーポレーテツド T細胞リダイレクト治療薬及び抗cd44治療薬を含む組成物
CN114316049B (zh) * 2021-12-24 2022-08-09 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543594A (en) * 1992-10-30 1994-05-24 Duke University An adhesion molecule
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
JPH10301492A (ja) * 1997-04-23 1998-11-13 Sony Corp 暗号化装置および方法、復号装置および方法、並びに情報処理装置および方法
ES2301525T3 (es) * 2000-01-21 2008-07-01 Sony Corporation Sistema de autentificacion de datos.
TW538636B (en) * 2000-09-01 2003-06-21 Matsushita Electric Industrial Co Ltd Reproduction equipment, reproduction equipment specifying equipment, reproduction equipment specifying system and methods and recording media for said equipment and system
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Also Published As

Publication number Publication date
DE602004029078D1 (de) 2010-10-21
CA2484459A1 (en) 2005-05-19
EP1692183B1 (en) 2010-09-08
EP1692183A2 (en) 2006-08-23
WO2005049082A3 (en) 2005-11-10
US20070237761A1 (en) 2007-10-11
US20050147606A1 (en) 2005-07-07
EP1532984A1 (en) 2005-05-25
JP2007513610A (ja) 2007-05-31
AU2004290918B2 (en) 2012-03-08
ATE480565T1 (de) 2010-09-15
US20070184051A1 (en) 2007-08-09
CA2546566A1 (en) 2005-06-02
WO2005049082A2 (en) 2005-06-02
AU2004290918A1 (en) 2005-06-02
CN1898268A (zh) 2007-01-17
US20100040540A1 (en) 2010-02-18
EP2275444A1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
KR102809618B1 (ko) Tslp에 결합하는 항체 및 이의 용도
KR102773187B1 (ko) Cldn18.2 항체 및 이의 용도
CN101849006B (zh) 改良的抗体分子
CN115151570B (zh) 抗人cd19抗体
KR102553870B1 (ko) 인간 카나비노이드 1(cb1) 수용체 결합 항체
KR102815628B1 (ko) 인간화 항-il17a 항체 및 이의 용도
CN101205255A (zh) 抗cd20四价抗体、其制备方法和应用
KR20110119720A (ko) 항-cd 160 모노클로널 항체 및 그 용도
KR20240019218A (ko) T 세포 관여자 분자 및 이의 용도
CN106573977A (zh) 针对ceacam1的人源化抗体
KR102478986B1 (ko) 암 치료용 항-ck8 항체
CN110945022A (zh) 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
KR20230152062A (ko) 항tslp 항체를 포함하는 의약 조성물
KR102802041B1 (ko) 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도
KR20210044262A (ko) Cd200r 효능제 항체 및 그의 용도
AU2020316498A1 (en) Humanized anti-VEGF monoclonal antibody
KR20230165285A (ko) Gdf15 신호전달의 치료적 억제제
CN112175087A (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
CN102030827A (zh) 一种高亲和力的抗her2单克隆抗体
KR20220151684A (ko) 암의 치료 및/또는 예방을 위한 의약품
CN104558194B (zh) 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
CN104610453A (zh) 一类抗her2双靶向抗体、其制备方法及用途
CN108948195B (zh) 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
CN104447993A (zh) 一种高活性全人源抗her2单克隆抗体、其制备方法及用途
AU2022290831B2 (en) Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060616

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110720

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130214

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130419

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20110720

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I